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OBJECTIVES The aim of this study was to determine whether selective cyclooxygenase-2 (COX-2)
inhibition with rofecoxib can modulate endothelial dysfunction and levels of circulating
inflammatory markers in patients with established coronary artery disease (CAD).
BACKGROUND Expression of COX-2 is upregulated in atherosclerosis. Thus, it has been hypothesized that
COX-2 may contribute to atherogenesis by producing eicosanoids, which mediate vascular
inflammation and endothelial dysfunction.
METHODS In a randomized, double-blind, placebo-controlled, parallel-design trial, we studied the
vascular effects of rofecoxib on brachial artery vasoreactivity and inflammatory markers in 60
patients with angiographically proven CAD who were taking concomitant low-dose aspirin.
Patients were randomly assigned to receive either rofecoxib (25 mg/day; n  30) or placebo
(n  30) for eight weeks. Brachial artery endothelium-dependent flow-mediated dilation
(FMD), endothelium-independent nitroglycerin-mediated dilation (NMD), and inflamma-
tory markers (i.e., high-sensitivity C-reactive protein [CRP], soluble intercellular adhesion
molecule-1 [sICAM-1], and soluble interleukin-6 receptor [sIL-6r]) were measured at
baseline and after eight-week follow-up.
RESULTS Baseline clinical characteristics were similar in the two groups. After eight weeks of treatment,
FMD did not significantly change in either the rofecoxib or placebo group (4.0  3.0% to
4.0  3.8% vs. 2.7  2.7% to 3.1  2.7%, respectively; p  0.6 by two-way analysis of
variance). Similarly, NMD remained unchanged in both groups. Levels of CRP, sICAM-1,
and sIL-6r were not significantly altered in either the rofecoxib or placebo group.
CONCLUSIONS The addition of selective COX-2 inhibition with rofecoxib did not appear to have any
favorable or adverse effects on endothelial dysfunction or vascular inflammation in patients
with CAD using concomitant low-dose aspirin. (J Am Coll Cardiol 2003;42:1747–53)
© 2003 by the American College of Cardiology Foundation
Increasingly, it has been recognized that both vascular
inflammation and endothelial dysfunction play a key role in
the pathogenesis of atherosclerosis (1,2). Clinically, there is
substantial evidence that elevated levels of circulating in-
flammatory markers, including high-sensitivity C-reactive
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protein (CRP), soluble intercellular adhesion molecule-1
(sICAM-1), and soluble interleukin-6, can predict the risk
of future cardiovascular events (2). This epidemiologic
association may be related to changes in endothelial func-
tion, as it has been shown that systemic inflammation can
impair endothelial function (3) and endothelial dysfunction
may be predictive of a poor prognosis (4). Moreover, there
is evidence that CRP may directly induce endothelial
dysfunction by reducing the release of endothelium-derived
nitric oxide (5). Thus, there may be a rationale for targeting
inflammation and endothelial dysfunction with novel anti-
inflammatory drugs to reduce cardiovascular events.
Cyclooxygenases convert arachidonic acid to prostaglan-
din G/H2, the precursor for prostacyclin, thromboxane A2,
prostaglandin E2, and other eicosanoids that are important
in vascular pathophysiology. Cyclooxygenase-2 (COX-2),
the inducible form of the enzyme, is expressed in athero-
sclerotic vessels but not in normal arteries (6,7). Thus, it has
been hypothesized that COX-2 may contribute to vascular
inflammation and atherosclerosis. This may have therapeu-
tic implications given the availability of selective COX-2
inhibitors such as rofecoxib and celecoxib, which could
suppress vascular inflammation and atherogenesis (6–11).
Conversely, there is evidence suggesting that the COX-2
enzyme may be protective against atherosclerosis (9,12).
Consequently, COX-2 inhibition may have adverse vascular
effects by altering the prostacyclin/thromboxane balance in
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favor of thromboxane (9,13). Clinically, the safety of the
COX-2 inhibitors has been recently questioned in the
VIoxx Gastrointestinal Outcomes Research (VIGOR)
study, which showed that rofecoxib was associated with
significantly more cardiovascular events (14). However, this
remains controversial, as other studies, including those
permitting concomitant low-dose aspirin, showed no in-
creased risk (15,16). Moreover, rofecoxib, despite blocking
prostacyclin production, does not appear to impair endo-
thelial function in healthy volunteers (17). Conversely, a
recent study has suggested that celecoxib may improve
endothelial dysfunction and reduce CRP levels in patients
with CAD on background aspirin therapy (18). Accord-
ingly, the aim of this study was to determine whether the
COX-2 inhibitor rofecoxib could modulate endothelial
dysfunction and markers of inflammation in patients with
established coronary artery disease (CAD) who were using
concomitant low-dose aspirin.
METHODS
Study design and study population. The study was a
randomized, double-blind, placebo-controlled, parallel-
design trial conducted between March 2001 and February
2002. The protocol was approved by the Queen Elizabeth II
Health Sciences Centre Research Ethics Committee.
Patients undergoing cardiac catheterization at the Queen
Elizabeth II Health Sciences Centre were screened for entry
into the trial. Patients between 18 and 75 years of age were
eligible if they had angiographically proven CAD, defined
as stenosis of 50% or more of the luminal diameter in a
major epicardial coronary vessel and stable angina pectoris
(Canadian Cardiovascular Society class I/II) within three
months of randomization. To minimize any confounding
effects on endothelium-dependent flow-mediated dilation
(FMD) and inflammatory markers, patients were excluded
if they had unstable angina, myocardial infarction, percuta-
neous coronary intervention or coronary artery bypass graft
surgery within three months of screening; an anticipated
need for bypass surgery or percutaneous coronary interven-
tion in the subsequent two months; uncontrolled hyperten-
sion; diabetes mellitus; ongoing congestive heart failure or
left ventricular ejection fraction 40%; or fasting total
cholesterol 6.0 mmol/l (232 mg/dl) with or without
lipid-lowering medications. Patients taking high-dose aspi-
rin (650 mg/day), nonsteroidal anti-inflammatory drugs
(NSAIDs), or COX-2 inhibitors within three months of
screening and those with known intolerance or sensitivity to
aspirin or COX-2 inhibitors, active peptic ulcer disease,
gastritis, esophagitis, or previous upper gastrointestinal
bleeding were also excluded. All patients received low-dose
aspirin (325 mg/day), which was maintained throughout the
study. Patients on lipid-lowering therapy and angiotensin-
converting enzyme (ACE) inhibitors were included, as long
as they were on a stable dose for two months before
enrollment. All patients gave written, informed consent. Of
the 135 consecutive patients screened, 60 were enrolled.
Study protocol. After enrollment, patients underwent
baseline clinical assessment and noninvasive assessment of
endothelial function. A fasting blood sample was obtained
on the morning of the endothelial function test for serum
lipids and inflammatory markers. Then, patients were ran-
domly assigned to one of two groups: placebo (n  30) or
rofecoxib (25 mg/day, Vioxx, Merck; n  30). This dose of
rofecoxib was chosen because it is associated with significant
inhibition of COX-2 (19). Moreover, it has been shown
that concomitant use of rofecoxib at this dose does not
antagonize the cardioprotective, antiplatelet effects of low-
dose aspirin (20). Randomization was performed according
to a sealed envelope assignment. Treatment assignments
were blinded, with matching placebo capsules. The assigned
treatment was continued for eight weeks. Patients and their
referring physicians were instructed to avoid additional
“open-label” COX-2 inhibitor or NSAID use during the
eight-week study. All patients were maintained on their
usual anti-anginal regimen throughout the study. Lipid-
lowering drugs and ACE inhibitors were maintained at
constant dosages throughout the study. None of the smok-
ers quit during the study. After eight weeks of treatment,
noninvasive endothelial function, serum lipids, and inflam-
matory markers were re-evaluated. Baseline and follow-up
endothelial function testing was carried out after a 12-h
overnight fast. Long-acting vasoactive medications were
withheld for 24 h before endothelial function testing, and
smokers refrained from smoking on the morning of the test.
Compliance at the end of eight weeks was assessed by a pill
count and was defined as taking 80% of the study
capsules.
Noninvasive assessment of endothelial function. Endo-
thelium-dependent and endothelium-independent dilation
of the brachial artery was assessed noninvasively using a
high-resolution ultrasound system (Philips HDI 5000,
Philips Medical Systems, Andover, Massachusetts) with a
7- to 12-MHz linear-array vascular transducer, as previously
described (4,21). The brachial artery was imaged longitudi-
nally, 2 to 15 cm above the antecubital crease, ensuring
optimal visualization of the anterior and posterior wall-
lumen interfaces. This position was maintained throughout
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the test, and a similar position was used in the follow-up
study. A pneumatic tourniquet placed proximally on the
forearm was inflated to 250 mm Hg for 5 min and rapidly
deflated, resulting in reactive hyperemia. Brachial artery
images were obtained continuously for 30 s before cuff
inflation (first baseline), at 50 to 110 s after cuff deflation
(post-reactive hyperemia), for another 30 s after 10-min rest
(second baseline), and for a further 60 s beginning 3 min
after sublingual nitroglycerin (0.3 mg). All images were
digitally recorded on magneto-optical disks for subsequent
off-line quantitative analysis.
During the baseline and second baseline phases, a total of
four end-diastolic frames (coincident with the peak of the
electrocardiographic R wave) were selected, acquiring one
frame every 5 s from the recorded digital sequences. End-
diastolic frames from three consecutive cardiac cycles were
selected at 60, 70, 80, and 90 s after cuff release to assess the
peak FMD response after reactive hyperemia. End-diastolic
frames from four consecutive cardiac cycles were selected at
3 min after sublingual nitroglycerin administration. Average
end-diastolic brachial artery diameters were measured using
commercially available, computer-assisted, brachial artery
quantitative software (Dynamic Endothelial Assessment,
Vasometrix, Montreal, Canada) by one observer blinded to
the patients’ treatment assignment. Unless the intima-
lumen border was clearly defined, the media-lumen border
for the anterior and posterior walls was determined by
automated edge-detection software over a 10- to 20-mm
arterial segment, and the average diameter over this segment
was determined (intra-assay coefficient of variation for
diameter 0.3%). The same region of interest was used for
measurements of the baseline, post-reactive hyperemia,
second baseline, and post-nitroglycerin images. Measure-
ments of the four sequential first baseline, second baseline,
and post-nitroglycerin frames were averaged at each phase.
Measurements of the three sequential post-reactive hyper-
emia frames at 60, 70, 80, and 90 s were averaged to
determine the maximal FMD diameter between 60 and
90 s. Endothelium-dependent FMD was defined as the
maximal percent change in brachial artery diameter (be-
tween 60 and 90 s) after reactive hyperemia compared with
baseline (intra-assay coefficient of variation for FMD
1.9%). Endothelium-independent nitroglycerin-mediated
dilation (NMD) was calculated as the percent change in
brachial artery diameter at 3 min after nitroglycerin com-
pared with the second baseline. Brachial artery flow was
calculated as the product of the Doppler velocity-time
integral, heart rate, and brachial artery cross-sectional area
(D2/4), where D average arterial diameter at that phase.
Reactive hyperemia was calculated as the percent change in
arterial flow after tourniquet deflation compared with base-
line.
Biochemical analyses. Venous blood was collected for
the measurement of serum lipids and the inflammatory
markers of high-sensitivity CRP, sICAM-1, and soluble
interleukin-6 receptor (sIL-6r). Serum was separated im-
mediately and frozen at 70°C for subsequent analysis.
Serum lipids were measured with a Beckman Synchron
CX7 system (Beckman Coulter, Inc., Brea, California).
Inflammatory markers were measured at McMaster Univer-
sity. High-sensitivity CRP levels were measured by nephe-
lometric assay (Dade-Behring, Inc., Deerfield, Illinois).
Levels of sICAM-1 and sIL-6r were measured with com-
mercially available ELISA assays (R&D Systems; Minne-
apolis, Minnesota).
Statistical analysis. Baseline characteristics of the two
groups were compared using one-way analysis of variance
(ANOVA) for continuous variables and the chi-square test
for categorical variables. The primary end point, the effect of
treatment on endothelium-dependent FMD and
endothelium-independent NMD over time, was assessed by
two-way repeated measures ANOVA on an intention-to-
treat basis. Secondary end points, the effects of treatment on
serum lipids and inflammatory markers, were also assessed
by two-way repeated measures ANOVA. As CRP,
sICAM-1, and sIL-6r levels values were skewed, a logarith-
mic transformation was performed, and the results are
expressed as geometric mean values. Linear regression was
used to assess the relationship between the change in FMD
and the change in inflammatory markers. Our sample size
was determined in order to demonstrate an absolute 2%
change in FMD (assuming a standard deviation of 2.5%) in
the rofecoxib group, compared with placebo (alpha  0.05
and beta  0.20; two-tailed test). Given the variability of
repeat FMD measurements, the minimal statistically signif-
icant change in FMD with intervention that can be detected
is 1.5% to 2.0% in parallel-design studies of 40 to 60
subjects (4). As previous studies with ACE inhibitors and
statins (both pharmacologic agents with proven clinical
cardioprotective effects) have shown an absolute 1.8% to
2.7% change in FMD (22,23), we believe an absolute 2%
change in FMD is clinically significant. Two-sided p values
0.05 were considered to indicate statistical significance.
Continuous data are expressed as the mean value  SD,
unless stated otherwise.
RESULTS
Patient characteristics. The baseline clinical and angio-
graphic characteristics for the two groups of patients are
shown in Table 1. There were no significant differences
between the two groups, although there was a trend toward
less ACE inhibitor use in the placebo group (p  0.07).
However, three-way ANOVA demonstrated no significant
interaction between ACE inhibitor use and the treatment
effect on FMD or inflammatory markers over time. Utili-
zation and dosages of ACE inhibitor and lipid-lowering
therapy did not change at follow-up.
Effects on FMD and NMD. End-diastolic brachial
artery diameters, brachial artery flow, and reactive hyper-
emia were similar in the two groups at baseline and
follow-up (Table 2). Heart rate and blood pressure were
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similar in the two groups at baseline and remained un-
changed at follow-up (data not shown).
Overall, the baseline FMD was 3.3  2.9%, which is
similar to that in previous reports on CAD patients using
lower arm occlusion (21,24). The FMD and NMD re-
sponses at baseline and follow-up for the two groups are
shown in Table 2. Although baseline FMD tended to be
higher in the rofecoxib group, this was not statistically
significant (4.0  3.0% vs. 2.6  2.7%; p  0.08). After
eight weeks of treatment, FMD did not significantly change
in either the placebo or rofecoxib group (p  0.6 by
two-way ANOVA) (Table 2).
Overall, endothelium-independent NMD was 14  5%.
At baseline, NMD was similar between the two groups and
remained unchanged at follow-up (p  0.6 by two-way
ANOVA) (Table 2).
Effects on serum lipids, CRP, sICAM-1, and sIL-6r.
Serum lipids, high-sensitivity CRP, sICAM-1, and sIL-6r
levels are shown in Table 3. The baseline lipids and
inflammatory markers were similar in both groups. Serum
lipids and circulating levels of the inflammatory markers
were not significantly altered in either the rofecoxib or
placebo group.
There were no significant correlations between the
change in maximal FMD at follow-up and the change in
any of the inflammatory markers at follow-up.
Follow-up, side effects, and compliance. During follow-
up, there were no cardiovascular events. In general, the
study medication was well tolerated, and side effects were
more commonly noted in the placebo group (27% vs. 20% in
rofecoxib group). Side effects included dyspepsia, heartburn,
epigastric discomfort, diarrhea, constipation, and rash.
There were no adverse effects on blood pressure or periph-
eral edema with rofecoxib. Based on pill counts, four
patients in the placebo group (13%) were thought to be
noncompliant with their study medications.
DISCUSSION
Our study shows that eight weeks of treatment with the
COX-2 inhibitor rofecoxib (25 mg/day) did not signifi-
cantly alter endothelium-dependent FMD or inflammatory
markers in patients with established CAD who were taking
concomitant low-dose aspirin.
To date, there are limited data on the direct vascular
effects of selective and nonselective COX inhibition. The
cardioprotective effects of aspirin, a nonselective COX
inhibitor, have largely been attributed to its antiplatelet
effects via thromboxane inhibition. Yet, aspirin may also act
through improving endothelial dysfunction (25,26) and
reducing inflammation (27,28). Husain et al. (25) demon-
strated that short-term administration of intravenous aspi-
rin improved acetylcholine-mediated vasodilation in pa-
tients with established atherosclerosis. Similarly, Kharbanda
et al. (26) demonstrated that pretreatment with high-dose
oral aspirin could prevent inflammation-induced endo-
thelial dysfunction. However, whether low-dose aspirin can
reduce circulating levels of CRP and other inflammatory
markers remains controversial (28,29). Verma et al. (17)
studied the effects of selective COX-2 versus nonselective
COX inhibition (with rofecoxib and naproxen, respectively)
on endothelium-dependent vasodilation in healthy volun-
teers. They found that selective COX-2 inhibition with
rofecoxib did not significantly alter acetylcholine-induced
Table 1. Clinical and Angiographic Characteristics of the
Study Patients
Characteristic
Placebo
(n  30)
Rofecoxib
(n  30)
Mean age (yrs) 58.3  7.1 57.5  8.0
Female gender (%) 7 10
Current smoker/ex-smoker (%) 13/63 0/63
History of dyslipidemia (%) 87 90
History of hypertension (%) 37 59
Previous MI (%) 47 47
Previous PCI (%) 57 50
Previous CABG (%) 47 37
Aspirin use (%) 100 100
Lipid-lowering therapy (%) 76 80
ACE inhibitors (%) 33 57
No. of vessels diseased (%)
1 33 35
2 27 17
3 40 48
CCS anginal class (%)
I 90 90
II 10 10
There were no significant differences for the characteristics listed.
ACE  angiotensin-converting enzyme; CABG  coronary artery bypass
grafting; CCS  Canadian Cardiovascular Society; MI  myocardial infarction;
PCI  percutaneous coronary intervention.
Table 2. Brachial Artery End-Diastolic Diameters and Flow,
Flow-Mediated Dilation, and Nitroglycerin-Mediated Dilation
Characteristic
Placebo
(n  30)
Rofecoxib
(n  30)
p
Value*
Brachial artery measurements
Basal end-diastolic
diameter (mm)
At baseline 4.61  0.74 4.32  0.69
At follow-up 4.54  0.74 4.34  0.70 0.4
Basal brachial artery flow
(ml/min)
At baseline 195  120 183  105
At follow-up 181  70 211  113 0.1
Reactive hyperemia (%)
At baseline 359  278 342  338
At follow-up 372  183 256  192 0.2
Flow-mediated dilation (%)
At baseline 2.7  2.7 4.0  3.0
At follow-up 3.1  2.7 4.0  3.8 0.6
Nitroglycerin-mediated
dilation (%)
At baseline 13.2  4.5 14.6  5.8
At follow-up 13.1  5.1 13.8  5.5 0.6
*The change in flow-mediated (and nitroglycerin-mediated) dilation from baseline to
follow-up was compared between the placebo and rofecoxib groups by two-way
analysis of variance for repeated measures. Data are presented as the mean value 
SD.
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vasodilation in these healthy subjects. Potentially, patients
with atherosclerosis may be more sensitive to the effects of
COX inhibition, as COX-dependent vasodilator prosta-
glandins are important in controlling vascular function in
subjects with atherosclerosis (30). Our findings are in
agreement with the results of Verma et al. (17) and extend
their findings to patients with established coronary athero-
sclerosis and endothelial dysfunction who are using con-
comitant low-dose aspirin. Conversely, Chenevard et al.
(18) recently studied the effect of the COX-2 inhibitor
celecoxib (200 mg twice daily for 2 weeks) on FMD and
CRP in a randomized, cross-over study in 14 patients with
CAD using concomitant aspirin and statins. In contrast to
our study, they found that celecoxib significantly improved
FMD (1.3% absolute increase) and reduced CRP levels.
These conflicting results may relate to differences in their
study design and small sample size or may reflect differences
between the cardiovascular effects of rofecoxib and cele-
coxib. Currently, it remains unknown whether such differ-
ences exist among the various selective COX-2 inhibitors
(10).
The use of COX-2 inhibitors in cardiovascular disease is
controversial. On one hand, there is evidence to suggest that
the COX-2 enzyme may have an important role in athero-
genesis, as COX-2 enzyme expression is upregulated within
atherosclerotic lesions (6,7). This increased COX-2 expres-
sion is localized to macrophages, endothelial cells, and
vascular smooth muscle cells within atherosclerotic plaque,
all of which are key players in the development and
progression of atherosclerosis. Thus, it has been speculated
that selective COX-2 inhibition may reduce vascular in-
flammation and atherosclerotic progression (6–11). In that
regard, a recent study has demonstrated that selective
COX-2 inhibition with rofecoxib significantly reduced ath-
erosclerosis formation in a low-density lipoprotein receptor-
deficient mouse model (11). Also, a recent open-label, pilot
study suggested there was benefit in adding the COX-2
inhibitor meloxicam to aspirin and heparin for preventing
recurrent cardiac events in patients with acute coronary
syndrome (31). Conversely, there is evidence suggesting
that the presence of COX-2 within atherosclerotic plaque
has a protective role in atherogenesis (9,12). Enhanced
COX-2 expression by endothelial cells increases the pro-
duction of prostacyclin over thromboxane A2, favoring an
antithrombotic state (13). Consequently, selective COX-2
inhibition may lead to prothrombotic effects by inhibiting
prostacyclin synthesis (8,9,12,13). Clinically, the recently
reported VIGOR study highlighted this potential concern
Table 3. Effects of Rofecoxib on Serum Lipids and Inflammatory Marker Levels
Variable
Placebo
(n  30)
Rofecoxib
(n  30)
p
Value*
Total cholesterol (mmol/l)†
Arithmetic mean  SD
At baseline 4.7  0.9 4.5  0.9
At follow-up 4.7  0.8 4.4  0.9 0.7
LDL cholesterol (mmol/l)†
Arithmetic mean  SD
At baseline 2.9  0.7 2.7  0.7
At follow-up 2.8  0.7 2.7  0.7 0.7
HDL cholesterol (mmol/l)†
Arithmetic mean  SD
At baseline 1.0  0.3 0.9  0.2
At follow-up 1.0  0.3 1.0  0.2 0.2
Triglycerides (mmol/l)‡
Arithmetic mean  SD
At baseline 1.7  0.9 1.9  0.9
At follow-up 1.7  0.8 1.8  0.8 0.3
High-sensitivity CRP (mg/l)§
Geometric mean value (95% CI)
At baseline 1.6 (1.1–2.3) 1.5 (1.0–2.1)
At follow-up 1.8 (1.2–2.8) 1.6 (1.0–2.5) 0.8
sICAM-1 (ng/ml)§
Geometric mean value (95% CI)
At baseline 263 (242–286) 272 (250–295)
At follow-up 259 (239–280) 268 (246–292) 0.9
sIL-6r (ng/ml)§
Geometric mean value (95% CI)
At baseline 33 (30–37) 34 (32–37)
At follow-up 33 (29–36) 33 (30–35) 0.9
*The changes in lipids, CRP, sICAM-1, and sIL-6r from baseline to follow-up were compared between the placebo and
rofecoxib groups by two-way analysis of variance for repeated measures. †To convert values for total cholesterol, LDL cholesterol,
and HDL cholesterol to mg/dl, divide by 0.02586. ‡To convert values for triglycerides to mg/dl, divide by 0.01129. §Normal
reference values for CRP: 0.5–2.5 mg/l; sICAM-1: 115–306 ng/ml; and sIL-6r: 14–46 ng/ml.
CI  confidence interval; CRP  C-reactive protein; HDL  high-density lipoprotein; LDL  low-density lipoprotein;
sICAM-1  soluble intercellular adhesion molecule-1; sIL-6r  soluble interleukin-6 receptor.
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of COX-2 blockade, as rofecoxib (50 mg/day) was associ-
ated with a significant increase in thrombotic cardiovascular
events, compared with the nonselective NSAID naproxen
(1,000 mg/day) when studied in over 8,000 patients with
rheumatoid arthritis (14). However, this report remains
controversial as the VIGOR findings were based on rela-
tively few events, and it is possible that the antiplatelet
effects of naproxen may have provided some cardioprotec-
tive effects (10,15). Moreover, further studies with rofecoxib
have shown no increase in cardiovascular risk, especially
when concomitant low-dose aspirin use was permitted
(15,16). Importantly, our mechanistic study cannot be
compared with the VIGOR trial, as we studied a lower dose
of rofecoxib (25 mg/day) and our study was not designed to
look at clinical events.
Study limitations. There are certain limitations to our
study. First, it is possible that rofecoxib may have effects on
endothelial function and vascular inflammation at the cel-
lular level, which are not detectable by measuring FMD and
nonspecific serum inflammatory markers. Second, the fail-
ure to demonstrate a significant effect on the serum inflam-
matory markers may be related to our low-risk, highly
selected, and small study population. It is possible that the
concomitant low-dose aspirin, statins, and ACE inhibitors
used in our study may have already suppressed the levels of
these markers within the normal range. Our study does not
allow us to determine the effects of rofecoxib independent of
this background treatment. Moreover, as acute coronary
syndromes may elevate levels of such markers, the effects of
rofecoxib may have been different in a less stable group of
patients (31). Also, the study was only powered according to
the expected effect on FMD and may have been too small to
detect a significant change in the serum markers of inflam-
mation. Third, we cannot be sure that our treatment period
was sufficiently long enough to alter endothelial function or
inflammatory markers. However, studies using other phar-
macologic interventions have demonstrated significant
treatment effects with treatment periods of eight weeks or
less in patients with CAD (18,22,23,28). Lastly, we did not
directly measure COX-2 inhibition with rofecoxib, al-
though previous studies have shown inhibition of COX-2
with a similar dose (19).
Conclusions. The addition of selective COX-2 inhibition
with rofecoxib did not appear to have any favorable or
adverse effects on endothelial dysfunction or vascular in-
flammation in stable CAD patients using concomitant
low-dose aspirin, along with frequent use of statins and
ACE inhibitors. As these findings differ with the recent
findings with celecoxib in CAD, additional mechanistic
studies may be required to compare the cardiovascular
effects of the various COX-2 inhibitors. Given the ongoing
controversy surrounding the use of COX-2 inhibitors,
further clinical studies with various COX-2 inhibitors are
clearly required to establish their safety and therapeutic
benefit in a wider spectrum of patients with CAD.
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